First launches for UCB's anti-epileptic Vimpat
This article was originally published in Scrip
UCBhas launched Vimpat (lacosamide), an anticonvulsant for treatment of adults with partial onset epilepsy in the UK, Germany and Austria following EU approval in September (Scrip Online, September 3rd, 2008). The launches are the first in the world. Vimpat can be administered via tablet, syrup or intravenously as an adjunctive therapy. In the UK, the daily cost of Vimpat is £5.15 for the 200mg tablet and £44.50 for an intravenous infusion.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.